FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAclaris Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ACRS
Aclaris Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Aclaris Therapeutics, Inc. (ACRS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisACRS
ACRS
Aclaris Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ACRS
  1. Home
  2. Stocks
  3. Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.

🇺🇸ACRS•NASDAQ

Aclaris Therapeutics, Inc.

🇺🇸ACRS•NASDAQ
Market cap
$555.14M

Your view on ACRS

Mkt Cap
$555.14M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Aclaris Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Neal S. Walker D.O.,
Headquarters
640 Lee Road, Wayne, PA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Neal S. Walker D.O.,
Headquarters
640 Lee Road, Wayne, PA, US
Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research.

The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services.

The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.

In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Aclaris Therapeutics, Inc.. Starting points for Aclaris Therapeutics, Inc.: EPS -$0.53, beta 0.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Aclaris Therapeutics, Inc.. Trailing twelve-month EPS for Aclaris Therapeutics, Inc. stands at -$0.53. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$9.17average of 6 firms, last 12 months
Current price—

Buy

Targets, low to high

$9.17

Low $3.00

Middle $10.00

High $12.00

Analyst ratings

4 firms, last 12 months
  • Strong Buy0
  • Buy4
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.16−$0.17−$0.60−$0.69
Lowest estimate−$0.17−$0.19−$0.61−$0.83
Highest estimate−$0.15−$0.15−$0.59−$0.61
Number of analysts8589
A year ago−$0.16−$0.15−$0.53—
Growth vs a year ago+0.5%−11.1%−12.6%—

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$1.37M$1.21M$6.37M$5.20M
Lowest estimate$232372.00$808333.00$5.38M$873500.00
Highest estimate$1.98M$1.62M$6.91M$9.71M
Number of analysts7578
A year ago$1.29M$2.00M$7.83M—
Growth vs a year ago+5.9%−39.3%−18.6%—
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Aclaris Therapeutics, Inc.. Aclaris Therapeutics, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ACRS19 companies · 8 funds
Compare ACRS with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AGMBAgomAb Therapeutics N.V. American Depositary SharesHealthcareBiotechnology$286.6M
ALDXAldeyra Therapeutics, Inc.HealthcareBiotechnology$40.5M
ALMSAlumis Inc. Common StockHealthcareBiotechnology$568.9M
ANABAnaptysBio, Inc.HealthcareBiotechnology$1.4B
IFRXInflaRx N.V.HealthcareBiotechnology$163.6M
IMUXImmunic, Inc.HealthcareBiotechnology$102.6M
MLTXMoonLake ImmunotherapeuticsHealthcareBiotechnology$918.3M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
CLDXCelldex Therapeutics, Inc.HealthcareNASDAQ$2.2B
CLGNCollPlant Biotechnologies Ltd.HealthcareNASDAQ$8.8M
CLLSCellectis S.A.HealthcareNASDAQ$103.8M
CLNNClene Inc.HealthcareNASDAQ$49.2M
CLRBCellectar Biosciences, Inc.HealthcareNASDAQ$8.9M
CLVLFClinuvel Pharmaceuticals LimitedHealthcareOTC$424.1M
CLYMClimb Bio, Inc.HealthcareNASDAQ$546.3M
CLYYFCelyad Oncology S.A.HealthcareOTC$6.7M
CMB.AXCambium Bio LimitedHealthcareASX—
CMMBChemomab Therapeutics Ltd.HealthcareNASDAQ$11.1M
CMNDClearmind Medicine Inc.HealthcareNASDAQ$1.6M
CMPSCOMPASS Pathways plcHealthcareNASDAQ$1.2B
ETFs holding Aclaris Therapeutics, Inc.
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
IWMiShares Russell 2000 ETF$76.6B in assets0.01%
VXFVanguard Extended Market ETF$30.2B in assets0.01%
XPHState Street SPDR S&P Pharmaceuticals ETF$516M in assets0.83%
DWASInvesco Dorsey Wright SmallCap Momentum ETF$376M in assets0.55%
SBIOALPS Medical Breakthroughs ETF$187M in assets0.36%
IWCiShares Micro-Cap ETF$1.2B in assets0.11%
VMO.TOVanguard Global Momentum Factor ETF$477M in assets0.11%

Largest holders first, then the funds most concentrated in ACRS.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Aclaris Therapeutics, Inc., and how their positions are changing. At a $555.1M market value, institutional positions materially move Aclaris Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Aclaris Therapeutics, Inc. executives and directors. Shares of Aclaris Therapeutics, Inc. have traded between $1.05 and $4.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Aclaris Therapeutics, Inc.. Coverage tracks Aclaris Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Aclaris Therapeutics, Inc.

ACRS AnalysisFair
Past
5
Growth
1
Health
5
Profit
1
Value
1